ferrous sulfate- ferrous sulfate 325 mg red tablet, film coated
ulai health llc - ferrous sulfate (unii: 39r4tan1vt) (ferrous cation - unii:gw89581owr) -
ferrous sulfate- ferrous sulfate 325 mg green tablet, film coated
ulai health llc - ferrous sulfate (unii: 39r4tan1vt) (ferrous cation - unii:gw89581owr) -
oyster shell calcium- oyster shell calcium 500mg tablet, coated
ulai health llc - calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6zb) -
high potency calcium- calcium 600mg and 5 mcg vitamin d3 tablet, film coated
ulai health llc - cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6zb) -
singulair oral granules 4 mgsachet
organon singapore pte. ltd. - montelukast sodium 4.160mg eqv montelukast - granule - 4 mg/packet - montelukast sodium 4.160mg eqv montelukast 4 mg/packet
singulair 4mg oral granules
organon malaysia sdn. bhd. - montelukast sodium -
singulair- montelukast sodium tablet, chewable singulair- montelukast sodium tablet, film coated
physicians total care, inc. - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - montelukast 4 mg - singulair® is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. singulair is indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 15 years of age and older. singulair is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older. hypersensitivity to any component of this product. pregnancy category b: there are no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, singulair should be used during pregnancy only if clearly needed. teratogenic effect: no teratogenicity was observed in rats and rabbits at doses approximately 100 and 110 times, respectively, the maximum recommended daily oral dose in adults based on aucs [see nonclinical toxicology (13.2)] . during worldwide marketing experience, congenital limb
singulair montelukast 4 mg (as sodium) tablet blister pack
organon pharma pty ltd - montelukast sodium, quantity: 4.16 mg (equivalent: montelukast, qty 4 mg) - tablet, chewable - excipient ingredients: aspartame; mannitol; iron oxide red; hyprolose; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; flavour - prophylaxis and treatment of chronic asthma in adults and children two years of age and over. symptomatic treatment of seasonal allergic rhinitis
singulair montelukast (as sodium) 5 mg chewable tablet blister
organon pharma pty ltd - montelukast sodium, quantity: 5.2 mg (equivalent: montelukast, qty 5 mg) - tablet, chewable - excipient ingredients: hyprolose; aspartame; mannitol; microcrystalline cellulose; croscarmellose sodium; iron oxide red; magnesium stearate; flavour - prophylaxis and treatment of chronic asthma in adults and children over two years. symptomatic treatment of seasonal allergic rhinitis
singulair montelukast (as sodium) 10 mg tablet blister pack
organon pharma pty ltd - montelukast sodium, quantity: 10.4 mg (equivalent: montelukast, qty 10 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; iron oxide yellow; titanium dioxide; carnauba wax; hypromellose; iron oxide red; lactose monohydrate; hyprolose; magnesium stearate - prophylaxis and treatment of chronic asthma in adults and children over two years. symptomatic treatment of seasonal allergic rhinitis